Thomas U. Marron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas U. Marron has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Sacha Gnjatic
Icahn School of Medicine at Mount Sinai, New York, New York, United States
99 shared publications - Andrea Wolf
Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
89 shared publications - Miriam Merad
Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA
82 shared publications - Raja M. Flores
Department of Thoracic Surgery Icahn School of Medicine at Mount Sinai New York New York USA
65 shared publications - Rachel Brody
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
50 shared publications - Robert P. Sebra
Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York USA
50 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
C-800-01 SAP 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Statistical analysis plan to support the main manuscript.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessC-800-01 SAP 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Statistical analysis plan to support the main manuscript.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
C-800-01 Protocol 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Clinical trial protocol to support the main manuscript.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessC-800-01 Protocol 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
Clinical trial protocol to support the main manuscript.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) Best overall response, (B) response over time, and (C) DOR in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025. an = 121 patients with percent change from baseline in tumor measurement. bResponse data for this patient were corrected because of a documented database error identified after database lock; correction reflects validated source data.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) Best overall response, (B) response over time, and (C) DOR in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025. an = 121 patients with percent change from baseline in tumor measurement. bResponse data for this patient were corrected because of a documented database error identified after database lock; correction reflects validated source data.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) PFS and (B) OS in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) PFS and (B) OS in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) Best overall response, (B) response over time, and (C) DOR in patients with MSS mCRC NLM previously exposed to available late-line therapiesa who received either dose of BOT + BAL. Data cutoff: December 13, 2025. aReceived ≥1 prior regimen of regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib. This was an exploratory, post hoc subgroup analysis.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases
(A) Best overall response, (B) response over time, and (C) DOR in patients with MSS mCRC NLM previously exposed to available late-line therapiesa who received either dose of BOT + BAL. Data cutoff: December 13, 2025. aReceived ≥1 prior regimen of regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib. This was an exploratory, post hoc subgroup analysis.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study
Purpose:MEDI1191 is a lipid nanoparticle–formulated messenger RNA (mRNA) designed to induce local interleukin (IL) 12 production and intensify antitumor T-cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800). Patients and Methods:Patients were ≥18 years with advanced/metastatic solid tumors and had progressed on ≥1 line of prior therapy (immunotherapy permitted). Cutaneous/subcutaneous (parts 1A and 1B) or deep-seated lesions (part 1D) were injected; patients had ≥1 noninjected lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions were noninjected. MEDI1191 and durvalumab were given sequentially (part 1A) or concurrently (parts 1B and 1D). Primary objectives were safety and determination of maximum tolerated dose (MTD). Secondary objectives included efficacy. Results:As of February 27, 2023, 61 patients were treated. Patients had a median of four prior regimens (range, 1–17); 39 (63.9%) received prior anti–programmed cell death protein 1/programmed cell death ligand 1 [PD-(L)1] immunotherapy. Treatment-emergent adverse events (TEAE) occurred in 96.7% of patients, and 41.0% experienced grade 3/4 TEAEs. There were no dose-limiting toxicities. The MTD was not reached. The objective response rate was 9.8%, including 1 confirmed complete response and 5 confirmed partial responses (PR). The duration of response was 2.7 to 22.3 months; the median was not reached. Responses occurred in injected lesions, local noninjected lesions, and distant lesions. Three of the 39 patients with prior anti–PD-(L)1 therapy had PRs. Conclusions:MEDI1191 and durvalumab were tolerated. Preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study
Purpose:MEDI1191 is a lipid nanoparticle–formulated messenger RNA (mRNA) designed to induce local interleukin (IL) 12 production and intensify antitumor T-cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800). Patients and Methods:Patients were ≥18 years with advanced/metastatic solid tumors and had progressed on ≥1 line of prior therapy (immunotherapy permitted). Cutaneous/subcutaneous (parts 1A and 1B) or deep-seated lesions (part 1D) were injected; patients had ≥1 noninjected lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Target lesions were noninjected. MEDI1191 and durvalumab were given sequentially (part 1A) or concurrently (parts 1B and 1D). Primary objectives were safety and determination of maximum tolerated dose (MTD). Secondary objectives included efficacy. Results:As of February 27, 2023, 61 patients were treated. Patients had a median of four prior regimens (range, 1–17); 39 (63.9%) received prior anti–programmed cell death protein 1/programmed cell death ligand 1 [PD-(L)1] immunotherapy. Treatment-emergent adverse events (TEAE) occurred in 96.7% of patients, and 41.0% experienced grade 3/4 TEAEs. There were no dose-limiting toxicities. The MTD was not reached. The objective response rate was 9.8%, including 1 confirmed complete response and 5 confirmed partial responses (PR). The duration of response was 2.7 to 22.3 months; the median was not reached. Responses occurred in injected lesions, local noninjected lesions, and distant lesions. Three of the 39 patients with prior anti–PD-(L)1 therapy had PRs. Conclusions:MEDI1191 and durvalumab were tolerated. Preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.